{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:01:36Z","timestamp":1784566896332,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20240146"],"award-info":[{"award-number":["BK20240146"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274233"],"award-info":[{"award-number":["82274233"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic retinopathy (DR) is a leading cause of blindness. While anti-vascular endothelial growth factor (VEGF) therapy is effective, its utility is limited by variable patient response and the need for frequent injections. Therefore, identifying new therapeutic targets for DR is imperative. Emerging evidence indicates that astrocytes contribute to endothelial dysfunction in DR, suggesting that targeting astrocyte-endothelial cell crosstalk represents a promising therapeutic strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the therapeutic potential of Salvianolic acid A (Sal A) for DR, elucidate the molecular mechanisms by which it modulates astrocyte-endothelial cell interactions, and develop a liposome-based nanodelivery system to enhance its efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>The protective effects and mechanisms of Sal A were systematically investigated using a streptozotocin (STZ)-induced diabetic mouse model, complemented by a suite of in vitro and molecular approaches including co-culture models, transcriptomic analysis, and target validation assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retinal vascular structure and barrier function were assessed in vivo via immunofluorescence staining and Evans Blue leakage assays. Endothelial cell behaviors were examined in vitro using wound healing, Transwell migration, tube formation, and spheroid sprouting assays. Transcriptomic profiling was performed by RNA sequencing (RNA-seq). The direct target of Sal A was identified and validated using MS-based drug-affinity responsive target stability (DARTS) screening, cellular thermal shift assay (CETSA), and microscale thermophoresis (MST). Expression of key signaling molecules was measured by western blotting, enzyme-linked immunosorbent assay (ELISA), and quantitative real-time PCR (qRT-PCR). Liposome@Sal A was prepared and characterized for its physicochemical properties (dynamic light scattering, transmission electron microscopy), stability, and therapeutic efficacy in vitro and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sal A treatment ameliorated retinal vascular abnormalities in diabetic mice, evidenced by increased VE-cadherin and NG2 expression, decreased \u03b1-smooth muscle actin (\u03b1-SMA) expression, and reduced acellular capillary formation, collectively restoring vascular integrity. Mechanistically, astrocyte-derived soluble Semaphorin 4D (sSema4D) promoted endothelial hyperactivation via the PlexinB1\/RhoA\/ROCK\/pMLC2 signaling cascade. Sal A directly bound to the Arg92 residue of membrane-bound Sema4D on astrocytes, significantly inhibiting sSema4D shedding and its subsequent deleterious effects on endothelial cells. Furthermore, Liposome@Sal A enhanced retinal drug delivery and demonstrated superior therapeutic efficacy compared to free Sal A in diabetic mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sal A preserves retinal vascular structure and function in DR by binding to astrocytic Sema4D at Arg92, thereby inhibiting sSema4D shedding and downstream PlexinB1\/RhoA\/ROCK\/pMLC2 signaling, which modulates astrocyte-endothelial cell crosstalk. Liposomal encapsulation significantly potentiates the therapeutic efficacy of Sal A, positioning it as a promising drug candidate for DR treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-026-01468-z","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T03:30:57Z","timestamp":1784518257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological manipulation of Sema4D by salvianolic acid A mitigates diabetic retinopathy via inhibiting PlexinB1\/RhoA\/ROCK\/pMLC2 signaling cascade involved in endothelial dysfunction"],"prefix":"10.1186","volume":"21","author":[{"given":"Weiwei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiliang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwenyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongjin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"1468_CR1","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128:1580\u201391.","journal-title":"Ophthalmology"},{"key":"1468_CR2","doi-asserted-by":"publisher","first-page":"2203351","DOI":"10.1002\/advs.202203351","volume":"10","author":"YN Li","year":"2023","unstructured":"Li YN, Liang HW, Zhang CL, Qiu YM, Wang D, Wang HL, et al. ophthalmic solution of smart supramolecular peptides to capture semaphorin 4D against diabetic retinopathy. Adv Sci (Weinh). 2023;10:2203351.","journal-title":"Adv Sci (Weinh)."},{"key":"1468_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13167-023-00314-8","volume":"14","author":"M Kropp","year":"2023","unstructured":"Kropp M, Golubnitschaja O, Mazurakova A, Koklesova L, Sargheini N, Vo TKS, et al. Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications-risks and mitigation. EPMA J. 2023;14:21\u201342.","journal-title":"EPMA J"},{"key":"1468_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41574-020-00451-4","volume":"17","author":"DA Antonetti","year":"2021","unstructured":"Antonetti DA, Silva PS, Stitt AW. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat Rev Endocrinol. 2021;17:195\u2013206.","journal-title":"Nat Rev Endocrinol"},{"key":"1468_CR5","doi-asserted-by":"crossref","unstructured":"Mrugacz M, Bryl A, Zorena K. Retinal vascular endothelial cell dysfunction and neuroretinal degeneration in diabetic patients. J Clin Med. 2021.\u00a0","DOI":"10.3390\/jcm10030458"},{"key":"1468_CR6","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/14712598.2022.2100694","volume":"22","author":"G Uludag","year":"2022","unstructured":"Uludag G, Hassan M, Matsumiya W, Pham BH, Chea S, Trong Tuong Than N, et al. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further? Expert Opin Biol Ther. 2022;22:1275\u201391.","journal-title":"Expert Opin Biol Ther"},{"key":"1468_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11739-019-02253-7","volume":"15","author":"M Porta","year":"2020","unstructured":"Porta M, Striglia E. Intravitreal anti-VEGF agents and cardiovascular risk. Intern Emerg Med. 2020;15:199\u2013210.","journal-title":"Intern Emerg Med"},{"key":"1468_CR8","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1136\/bjophthalmol-2016-308388","volume":"100","author":"M Ashraf","year":"2016","unstructured":"Ashraf M, Souka A, Adelman R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. Br J Ophthalmol. 2016;100:1596\u2013604.","journal-title":"Br J Ophthalmol"},{"key":"1468_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00018-023-05024-y","volume":"81","author":"M Llorian-Salvador","year":"2024","unstructured":"Llorian-Salvador M, Cabeza-Fernandez S, Gomez-Sanchez JA, de la Fuente AG. Glial cell alterations in diabetes-induced neurodegeneration. Cell Mol Life Sci. 2024;81:47.","journal-title":"Cell Mol Life Sci"},{"key":"1468_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.347","volume":"7","author":"JH Yun","year":"2016","unstructured":"Yun JH, Park SW, Kim JH, Park YJ, Cho CH, Kim JH. Angiopoietin 2 induces astrocyte apoptosis via alphavbeta5-integrin signaling in diabetic retinopathy. Cell Death Dis. 2016;7:e2101.","journal-title":"Cell Death Dis"},{"key":"1468_CR11","first-page":"2423","volume":"38","author":"TW Gardner","year":"1997","unstructured":"Gardner TW, Lieth E, Khin SA, Barber AJ, Bonsall DJ, Lesher T, et al. Astrocytes increase barrier properties and ZO-1 expression in retinal vascular endothelial cells. Invest Ophthalmol Vis Sci. 1997;38:2423\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1468_CR12","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201810154","volume":"12","author":"JH Wu","year":"2020","unstructured":"Wu JH, Li YN, Chen AQ, Hong CD, Zhang CL, Wang HL, et al. Inhibition of Sema4D\/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy. EMBO Mol Med. 2020;12:e10154.","journal-title":"EMBO Mol Med"},{"key":"1468_CR13","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/j.1460-9568.1993.tb00963.x","volume":"5","author":"E Rungger-Brandle","year":"1993","unstructured":"Rungger-Brandle E, Messerli JM, Niemeyer G, Eppenberger HM. Confocal microscopy and computer-assisted image reconstruction of astrocytes in the mammalian retina. Eur J Neurosci. 1993;5:1093\u2013106.","journal-title":"Eur J Neurosci"},{"key":"1468_CR14","first-page":"339","volume":"39","author":"JH Kim","year":"2006","unstructured":"Kim JH, Kim JH, Park JA, Lee SW, Kim WJ, Yu YS, et al. Blood-neural barrier: intercellular communication at glio-vascular interface. J Biochem Mol Biol. 2006;39:339\u201345.","journal-title":"J Biochem Mol Biol"},{"key":"1468_CR15","first-page":"163","volume":"13","author":"CY Su","year":"2015","unstructured":"Su CY, Ming QL, Rahman K, Han T, Qin LP. Salvia miltiorrhiza: traditional medicinal uses, chemistry, and pharmacology. Chin J Nat Med. 2015;13:163\u201382.","journal-title":"Chin J Nat Med"},{"key":"1468_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2019.152871","volume":"58","author":"Q Jia","year":"2019","unstructured":"Jia Q, Zhu R, Tian Y, Chen B, Li R, Li L, et al. Salvia miltiorrhiza in diabetes: a review of its pharmacology, phytochemistry, and safety. Phytomedicine. 2019;58:152871.","journal-title":"Phytomedicine"},{"key":"1468_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.lfs.2009.07.018","volume":"85","author":"SB Wang","year":"2009","unstructured":"Wang SB, Yang XY, Tian S, Yang HG, Du GH. Effect of salvianolic acid A on vascular reactivity of streptozotocin-induced diabetic rats. Life Sci. 2009;85:499\u2013504.","journal-title":"Life Sci"},{"key":"1468_CR18","doi-asserted-by":"publisher","first-page":"106986","DOI":"10.1016\/j.phrs.2023.106986","volume":"198","author":"W Zheng","year":"2023","unstructured":"Zheng W, Shen P, Yu C, Tang Y, Qian C, Yang C, et al. Ginsenoside Rh1, a novel casein kinase II subunit alpha (CK2alpha) inhibitor, retards metastasis via disrupting HHEX\/CCL20 signaling cascade involved in tumor cell extravasation across endothelial barrier. Pharmacol Res. 2023;198:106986.","journal-title":"Pharmacol Res"},{"key":"1468_CR19","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s00125-018-4770-4","volume":"62","author":"KK Ting","year":"2019","unstructured":"Ting KK, Zhao Y, Shen W, Coleman P, Yam M, Chan-Ling T, et al. Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models. Diabetologia. 2019;62:322\u201334.","journal-title":"Diabetologia"},{"key":"1468_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106333","volume":"182","author":"C Qian","year":"2022","unstructured":"Qian C, Yang C, Tang Y, Zheng W, Zhou Y, Zhang S, et al. Pharmacological manipulation of Ezh2 with salvianolic acid B results in tumor vascular normalization and synergizes with cisplatin and T cell-mediated immunotherapy. Pharmacol Res. 2022;182:106333.","journal-title":"Pharmacol Res"},{"key":"1468_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12951-024-02330-w","volume":"22","author":"X Wang","year":"2024","unstructured":"Wang X, Xu C, Bian C, Ge P, Lei J, Wang J, et al. M2 microglia-derived exosomes promote vascular remodeling in diabetic retinopathy. J Nanobiotechnology. 2024;22:56.","journal-title":"J Nanobiotechnology"},{"key":"1468_CR22","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12964-025-02441-3","volume":"23","author":"VO Oria","year":"2025","unstructured":"Oria VO, Castro JL, de Pina RJ, Martinez AG, Jorgensen FI, Lukassen MV, et al. Crosstalk between tumor endothelial cells and cancer cells is important for metastasis initiation. Cell Commun Signal. 2025;23:443.","journal-title":"Cell Commun Signal."},{"key":"1468_CR23","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/j.apsb.2024.02.003","volume":"14","author":"C Qian","year":"2024","unstructured":"Qian C, Zhou Y, Zhang T, Dong G, Song M, Tang Y, et al. Targeting PKM2 signaling cascade with salvianic acid A normalizes tumor blood vessels to facilitate chemotherapeutic drug delivery. Acta Pharm Sin B. 2024;14:2077\u201396.","journal-title":"Acta Pharm Sin B"},{"key":"1468_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155180","volume":"123","author":"C Yang","year":"2024","unstructured":"Yang C, Qian C, Zheng W, Dong G, Zhang S, Wang F, et al. Ginsenoside Rh2 enhances immune surveillance of natural killer (NK) cells via inhibition of ERp5 in breast cancer. Phytomedicine. 2024;123:155180.","journal-title":"Phytomedicine"},{"key":"1468_CR25","doi-asserted-by":"crossref","unstructured":"Zhi Y, Pan L, Xiong W, Lam TC, Xiao H, Do CW. Ocular and systemic pharmacokinetics of Baicalein and Baicalin after intravitreal injection and oral administration in mice. Pharmaceutics. 2026.\u00a0","DOI":"10.3390\/pharmaceutics18020243"},{"key":"1468_CR26","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.7150\/thno.83532","volume":"13","author":"M Xia","year":"2023","unstructured":"Xia M, Jiao L, Wang XH, Tong M, Yao MD, Li XM, et al. Single-cell RNA sequencing reveals a unique pericyte type associated with capillary dysfunction. Theranostics. 2023;13:2515\u201330.","journal-title":"Theranostics"},{"key":"1468_CR27","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.63.5.8","volume":"63","author":"D An","year":"2022","unstructured":"An D, Chung-Wah-Cheong J, Yu DY, Balaratnasingam C. Alpha-smooth muscle actin expression and parafoveal blood flow pathways are altered in preclinical diabetic retinopathy. Invest Ophthalmol Vis Sci. 2022;63:8.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1468_CR28","doi-asserted-by":"publisher","first-page":"976","DOI":"10.4103\/1673-5374.355743","volume":"18","author":"L Tang","year":"2023","unstructured":"Tang L, Xu GT, Zhang JF. Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy. Neural Regen Res. 2023;18:976\u201382.","journal-title":"Neural Regen Res"},{"key":"1468_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10456-023-09895-4","volume":"26","author":"AC Dudley","year":"2023","unstructured":"Dudley AC, Griffioen AW. The modes of angiogenesis: an updated perspective. Angiogenesis. 2023;26:477\u201380.","journal-title":"Angiogenesis"},{"key":"1468_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ceb.2015.06.007","volume":"36","author":"G Jacquemet","year":"2015","unstructured":"Jacquemet G, Hamidi H, Ivaska J. Filopodia in cell adhesion, 3D migration and cancer cell invasion. Curr Opin Cell Biol. 2015;36:23\u201331.","journal-title":"Curr Opin Cell Biol"},{"key":"1468_CR31","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1038\/s41467-025-58074-0","volume":"16","author":"K He","year":"2025","unstructured":"He K, Dong X, Yang T, Li Z, Liu Y, He J, et al. Smoking aggravates neovascular age-related macular degeneration via Sema4D-PlexinB1 axis-mediated activation of pericytes. Nat Commun. 2025;16:2821.","journal-title":"Nat Commun"},{"key":"1468_CR32","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/1078-0432.CCR-15-0431","volume":"22","author":"A Patnaik","year":"2016","unstructured":"Patnaik A, Weiss GJ, Leonard JE, Rasco DW, Sachdev JC, Fisher TL, et al. Safety, pharmacokinetics, and pharmacodynamics of a humanized anti-semaphorin 4D antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res. 2016;22:827\u201336.","journal-title":"Clin Cancer Res"},{"key":"1468_CR33","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.63.8.22","volume":"63","author":"H Zhao","year":"2022","unstructured":"Zhao H, Kong H, Wang W, Chen T, Zhang Y, Zhu J, et al. High glucose aggravates retinal endothelial cell dysfunction by activating the RhoA\/ROCK1\/pMLC\/Connexin43 signaling pathway. Invest Ophthalmol Vis Sci. 2022;63:22.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1468_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03500-w","volume":"20","author":"L Liu","year":"2022","unstructured":"Liu L, Yang L, Liu X, Liu M, Liu J, Feng X, et al. SEMA4D\/PlexinB1 promotes AML progression via activation of PI3K\/Akt signaling. J Transl Med. 2022;20:304.","journal-title":"J Transl Med"},{"key":"1468_CR35","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1096\/fj.201700786RR","volume":"32","author":"YF Zhou","year":"2018","unstructured":"Zhou YF, Li YN, Jin HJ, Wu JH, He QW, Wang XX, et al. Sema4D\/PlexinB1 inhibition ameliorates blood-brain barrier damage and improves outcome after stroke in rats. FASEB J. 2018;32:2181\u201396.","journal-title":"FASEB J"},{"key":"1468_CR36","doi-asserted-by":"publisher","first-page":"13614","DOI":"10.1002\/jcb.28635","volume":"120","author":"T Zou","year":"2019","unstructured":"Zou T, Jiang S, Dissanayaka WL, Heng BC, Xu J, Gong T, et al. Sema4D\/PlexinB1 promotes endothelial differentiation of dental pulp stem cells via activation of AKT and ERK1\/2 signaling. J Cell Biochem. 2019;120:13614\u201324.","journal-title":"J Cell Biochem"},{"key":"1468_CR37","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12951-023-02165-x","volume":"21","author":"C Qiu","year":"2023","unstructured":"Qiu C, Zhang JZ, Wu B, Xu CC, Pang HH, Tu QC, et al. Advanced application of nanotechnology in active constituents of Traditional Chinese Medicines. J Nanobiotechnology. 2023;21:456.","journal-title":"J Nanobiotechnology."},{"key":"1468_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1009229","volume":"13","author":"J Zhu","year":"2022","unstructured":"Zhu J, Chen H, Le Y, Guo J, Liu Z, Dou X, et al. Salvianolic acid A regulates pyroptosis of endothelial cells via directly targeting PKM2 and ameliorates diabetic atherosclerosis. Front Pharmacol. 2022;13:1009229.","journal-title":"Front Pharmacol"},{"key":"1468_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.111162","volume":"400","author":"J Zhu","year":"2024","unstructured":"Zhu J, Guo J, Liu Z, Liu J, Yuan A, Chen H, et al. Salvianolic acid A attenuates non-alcoholic fatty liver disease by regulating the AMPK-IGFBP1 pathway. Chem Biol Interact. 2024;400:111162.","journal-title":"Chem Biol Interact"},{"key":"1468_CR40","doi-asserted-by":"publisher","first-page":"11216","DOI":"10.3390\/molecules170911216","volume":"17","author":"X Yu","year":"2012","unstructured":"Yu X, Zhang L, Yang X, Huang H, Huang Z, Shi L, et al. Salvianolic acid A protects the peripheral nerve function in diabetic rats through regulation of the AMPK-PGC1alpha-Sirt3 axis. Molecules. 2012;17:11216\u201328.","journal-title":"Molecules"},{"key":"1468_CR41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00125-007-0886-7","volume":"51","author":"S Lenzen","year":"2008","unstructured":"Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 2008;51:216\u201326.","journal-title":"Diabetologia"},{"key":"1468_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature13165","volume":"508","author":"CN Hall","year":"2014","unstructured":"Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland BA, et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. 2014;508:55\u201360.","journal-title":"Nature"},{"key":"1468_CR43","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1038\/s41467-018-05926-7","volume":"9","author":"A Dubrac","year":"2018","unstructured":"Dubrac A, Kunzel SE, Kunzel SH, Li J, Chandran RR, Martin K, et al. NCK-dependent pericyte migration promotes pathological neovascularization in ischemic retinopathy. Nat Commun. 2018;9:3463.","journal-title":"Nat Commun"},{"key":"1468_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2023.101217","volume":"97","author":"L Alarcon-Martinez","year":"2023","unstructured":"Alarcon-Martinez L, Shiga Y, Villafranca-Baughman D, Cueva Vargas JL, Vidal Paredes IA, Quintero H, et al. Neurovascular dysfunction in glaucoma. Prog Retin Eye Res. 2023;97:101217.","journal-title":"Prog Retin Eye Res"},{"key":"1468_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.clim.2015.12.012","volume":"163","author":"KT Maleki","year":"2016","unstructured":"Maleki KT, Cornillet M, Bjorkstrom NK. Soluble SEMA4D\/CD100: a novel immunoregulator in infectious and inflammatory diseases. Clin Immunol. 2016;163:52\u20139.","journal-title":"Clin Immunol"},{"key":"1468_CR46","doi-asserted-by":"publisher","first-page":"100832","DOI":"10.1016\/j.mtbio.2023.100832","volume":"23","author":"Y Cui","year":"2023","unstructured":"Cui Y, Jiang X, Yang M, Yuan Y, Zhou Z, Gao X, et al. SEMA4D\/VEGF surface enhances endothelialization by diminished-glycolysis-mediated M2-like macrophage polarization. Mater Today Bio. 2023;23:100832.","journal-title":"Mater Today Bio"},{"key":"1468_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10585-018-9951-5","volume":"36","author":"WG Chen","year":"2019","unstructured":"Chen WG, Sun J, Shen WW, Yang SZ, Zhang Y, Hu X, et al. Sema4D expression and secretion are increased by HIF-1alpha and inhibit osteogenesis in bone metastases of lung cancer. Clin Exp Metastasis. 2019;36:39\u201356.","journal-title":"Clin Exp Metastasis"},{"key":"1468_CR48","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.devcel.2013.08.020","volume":"26","author":"M Giannotta","year":"2013","unstructured":"Giannotta M, Trani M, Dejana E. VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev Cell. 2013;26:441\u201354.","journal-title":"Dev Cell"},{"key":"1468_CR49","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1039\/D3NH00120B","volume":"8","author":"YL Zhang","year":"2023","unstructured":"Zhang YL, Wang YL, Yan K, Deng QQ, Li FZ, Liang XJ, et al. Nanostructures in Chinese herbal medicines (CHMs) for potential therapy. Nanoscale Horiz. 2023;8:976\u201390.","journal-title":"Nanoscale Horiz"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01468-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-026-01468-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01468-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:02:07Z","timestamp":1784563327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-026-01468-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1468"],"URL":"https:\/\/doi.org\/10.1186\/s13020-026-01468-z","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"15 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal studies were approved by the Animal Committee of Nanjing University of Chinese Medicine (approved number: 202312A069). Human umbilical vein ECs (HUVECs) were isolated from donated cords with approval from the Ethics Committee of Jiangsu Province Hospital on Integration of Chinese and Western Medicine (permit and approval number: 2021-LWKY-003).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"198"}}